Lexaria Bioscience Corp. LXRP Archives - Page 10 of 27

ThursdayApr 25, 2019 9:45 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Expands Advisory Board; Subsidiary Enters Beverage License Agreement

Biotechnology company and drug delivery platform innovator Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) on Wednesday announced that, through its subsidiary Lexaria CanPharm ULC, it has entered a definitive 5-year agreement to provide Lexaria's patented DehydraTECH(TM) technology to a private California-based cannabis company. Under the agreement the cannabis company will utilize the technology in certain cannabis-based beverages to be produced and sold in the states of California and Nevada. DehydraTECH-enabled beverages are protected under Lexaria's many existing US-granted patents and may include any combination of ready-to-drink beverages such as non-alcoholic beers, wines and spirits; cold or hot coffee or teas, sports…

MondayApr 15, 2019 12:10 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Advancing DehydraTECH Drug Delivery Platform, Innovative Products

Lexaria Bioscience is focusing on its pioneering DehydraTECH drug delivery technology The company boasts a portfolio of unique products Lexaria continues to conduct research regarding DehydraTECH technology for oral nicotine Based in Kelowna, British Columbia, Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) focuses on technology for the improved delivery of bioactive compounds. Lexaria is the only global company with patents issued for the oral delivery of all cannabinoids. The company has developed and out-licenses its innovative and cost-effective DehydraTECH drug delivery platform. This technology changes the way that edible cannabinoids enter the body. DehydraTECH delivery technology offers a viable and…

MondayApr 15, 2019 8:59 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Retains Oak Hill Financial Inc. for IR Services

Biotechnology company and drug delivery platform innovator Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) this morning announced that it has retained Oak Hill Financial Inc. to provide investor relations services to the company in compliance with regulatory guidelines. Per the update, Oak Hill is a Toronto-based firm that develops strategic platforms for its clients that are utilized to gain exposure and recognition in the capital markets. Oak Hill is expected to work closely with Lexaria to “develop and deploy a comprehensive capital markets strategy and campaign. Activities will include providing an investor relations program catering to retail investors, marketing services…

TuesdayApr 09, 2019 9:29 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Renews Senior Management Contracts, Cancels Options

Biotechnology company and drug delivery platform innovator Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) this morning announced its successful negotiation of renewal management contracts with chief executive officer Chris Bunka and president John Docherty. According to the update, the new 3-year term contracts, for which specific details can be found within regulatory filings, provide management continuity during this period of corporate growth while allowing the company to seamlessly pursue its business goals and create shareholder value. In addition, Lexaria announced that, effective April 5, 2019, it has reached agreements with certain optionees to cancel 1,140,000 stock options with exercise prices ranging…

FridayApr 05, 2019 2:54 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) DehydraTECH Technology Revolutionizes CBD Delivery

Biotechnology company Lexaria Bioscience’s (CSE: LXX) (OTCQX: LXRP) innovative drug-delivery platform DehydraTECH(TM) alters the way cannabinoids enter the bloodstream, which results in increased absorption. A recent article discussing LXRP reads, “Its proprietary technology promises multiple advantages in cannabinoid edibles. First, it masks the undesirable taste typically found in cannabinoid edibles, eliminating the need to add sweetening agents and enabling sugar-free options. Second, it increases the product’s absorption rate, with absorption occurring at two- to five-times higher rates than other edibles. Finally, it reduces the time of onset; effects of the product are felt within 15–20 minutes of consumption rather than…

FridayApr 05, 2019 12:26 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) CEO Talks DehydraTECH’s Lifesaving Technology on CEO Clips

LXRP CEO Chris Bunka explained in the interview that proprietary technology can save 60,000 lives annually if consumption habits of even one percent of smokers worldwide change CEO Clips videos are featured on business sites including BNN Bloomberg, Thomson Reuters, Yahoo! Finance and Stockhouse.com Bunka went on to described LXRP’s growing patent portfolio and noted that ingesting rather than inhaling, using DehydraTECH technology, could be a lifesaver Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) CEO Chris Bunka sought to raise awareness of LXRP in the financial community as he appeared, March 23-24, on CEO Clips via YouTube. In the video,…

MondayApr 01, 2019 12:55 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Launches Its Largest Cannabinoid Research Program

The R&D program will focus on the proprietary Lexaria DehydraTECH delivery technology with the purpose of enhancing it further Results could contribute to new patent filings in the future; in addition, the program will examine more extensively the way DehydraTECH-enabled CBD outperforms generic CBD Lexaria-designed nanotech enhancements will also be included in the program Biotechnology company and drug delivery platform innovator Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is launching its largest cannabinoid research and development program to date. The program consists of 11 separate animal studies, according to a company press release (http://ibn.fm/xidEM). The Lexaria in vitro study design was…

FridayMar 29, 2019 12:02 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP) Utilizes Disruptive Technology for Improved Delivery of Bioactive Compounds

Biotechnology company and drug-delivery platform innovator Lexaria Bioscience (CSE: LXX) (OTC: LXRP) utilizes disruptive technology for the improved delivery of bioactive compounds. A recent article discussing this reads, “Lexaria’s technology has been shown to be effective in numerous global studies, significantly assisting rapidity and quantity of absorption for a range of lipophilic (fat-soluble), bioactive molecules. In essence, the company disrupts the manner in which cannabinoids enter the bloodstream through the gastrointestinal tract (http://ibn.fm/CsUCz). Lexaria’s emphasis on oral ingestion provides a practical and often healthier option to other delivery methods for bioactive substances used extensively today. This includes inhalational delivery via…

TuesdayMar 26, 2019 11:53 am

Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) Revolutionary Technology is Disrupting the Cannabis Edibles Industry

Lexaria Bioscience Corp. is the only company worldwide with patents issued for oral delivery of all cannabinoids Its proprietary technology bests traditional methods such as inhalation in several key ways The company continues to enhance its intellectual property portfolio as it pursues patents around the world Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), a food biosciences company, has developed a proprietary technology that has revolutionized the way cannabidiol (CBD) and other non-psychoactive cannabinoids are delivered into the bloodstream. Lexaria, the only company worldwide with patents issued for oral delivery of all cannabinoids, has greatly improved the delivery of bioactive compounds.…

ThursdayMar 21, 2019 9:41 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP) Launches its Largest Cannabinoid R&D Program

Biotechnology company and drug delivery platform innovator Lexaria Bioscience (CSE: LXX) (OTC: LXRP) on Wednesday announced that work has commenced on its largest-ever cannabinoid research program, which will also test Lexaria-designed nanotech enhancements. According to the update, the new program is comprised of 11 separate animal studies, each comparable in scope to individual animal studies the company conducted during 2018. Six months ago, Lexaria began its 2019 in vivo study design. All laboratory test articles have been produced and exceed all required quality control thresholds, and the project has now advanced to the implementation stage. The 2019 R&D project is…

Site Search

Company Search

Tag: Lexaria Bioscience Corp. LXRP